Changes in symptom and quality of life in patients with uncontrolled asthma treated with Budesonide/Glycopyrronium/Formoterol fumarate metered dose inhaler (BGF MDI) - BENTEN

Study identifier:D5980R00145

ClinicalTrials.gov identifier:NCT07933510

EudraCT identifier:N/A

CTIS identifier:N/A

Will Be Recruiting

Official Title

BENTEN study: Changes in symptom and quality of life in patients with uncontrolled asthma treated with Budesonide/Glycopyrronium/Formoterol fumarate metered dose inhaler (BGF MDI): a prospective, multi-centers, observational study

Medical condition

asthma

Phase

-

Healthy volunteers

no

Study drug

Budesonide/Glycopyrronium/Formoterol fumarate metered dose inhaler

Sex

All

Estimated Enrollment

200

Study type

Observational

Age

18 Years +

Date

Study Start Date: 29 Jan 2027
Estimated Primary Completion Date: 31 Aug 2027
Estimated Study Completion Date: 31 Aug 2027

Study design

Allocation: -
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -

Verification:

Verified 01 Nov 2026 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

-

Inclusion and exclusion criteria